ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0849

Association of Prehospital RAAS Inhibitor Use with AKI and Death in a Cohort of Hospitalized COVID-19-Infected Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Mocerino, Ryan, Montefiore Medical Center, Bronx, New York, United States
  • Alahiri, Emad, Montefiore Medical Center, Bronx, New York, United States
  • Abramowitz, Matthew K., Montefiore Medical Center, Bronx, New York, United States
  • Golestaneh, Ladan, Montefiore Medical Center, Bronx, New York, United States
Background

The relationship of RAAS inhibitors (RAASi) and their purported role in increasing COVID-19 viral attachment and worse outcomes is controversial. In this study we examined the association of RAASi use with Acute Kidney Injury (AKI) and in-hospital death.

Methods

We assembled a cohort of all patients admitted to the 3 main Montefiore hospitals and diagnosed with COVID-19. RAASi use was defined by a prescription within 365 days prior to hospitalization. The association of RAASi use with COVID associated AKI incidence and mortality was evaluated using logistic regression models. Propensity score matching was then used to derive the odds ratio (OR) of AKI and death in those using RAASi compared with controls.

Results

Of 3345 hospitalized patients, 9.3% were prescribed a RAASi prior to hospitalization. Those prescribed RAASi were older (71.9 vs 63.6 years, p<0.001), more commonly Black or Hispanic (RAASi users 41.3% Black and 41.0% Hispanic vs non-RAASi 35.4% Black and 36.9% Hispanic) and had higher Charlson co-morbidity scores (median 4 (IQR 3-7) for RAASi users vs 2(1-3) for non-RAASi users). In unadjusted analysis, RAASi use was associated with a higher OR for AKI (OR 1.32(95% CI 1.04-1.68)) and a higher OR for death (OR 1.53 (95% CI 1.18-1.98). Multivariate adjustment for age, demographics, and clinical comorbidity attenuated associations of AKI and death towards the null (AKI: OR 1.00 (95% CI 0.76-1.31); Death: OR 0.92 (95% CI 0.68-1.24)). Similarly, in propensity score analysis there was no association between RAASi use and either AKI (OR 0.96 (95%CI 0.88-1.04)) or death (OR: 0.96 (95%CI 0.89-1.05).

Conclusion

RAASi use prior to hospitalization was not associated with AKI or in-hospital mortality in a cohort of patients hospitalized with COVID-19.